Current and past smokers face greater risk for hip replacement failure
Smoking has been linked to prolonged healing time and greater risk for complications in orthopaedic and other surgeries, according to a new study of the American Academy of Orthopaedic Surgeons (AAOS).
Researchers reviewed records of all total hip replacement (THR, or total hip arthroplasty) patients between 2007 and 2009 to identify patients who used tobacco products at the time of surgery, or who smoked regularly prior to surgery.
There were 110 patients who regularly smoked, with a mean age of 55 and a mean follow up of 46 months following THR. A control group was matched 2:1 with the smoking group based on gender, date of surgery within six months, age within five years, related medical conditions (co-morbidities) and immunosuppressive conditions. The smoking group was categorized as current or former smokers, and according to the number of packs of cigarettes smoked per year.
At the most recent follow up, the patients who smoked had a 92 percent survival rate compared to 99 percent for non smokers. Of the nine THR revisions in smokers, four were done to alleviate pain and/or to repair a loose acetabular component (the hip socket), and five resulted from infection. Of the current smokers, six of 65 had revisions (9.2 percent); of the former smokers, 2 out of 45 patients (4.4 percent).
Overall, the patients who smoked had a higher overall revision rate and a higher incidence of other complications. The study authors recommend smoking cessation programs for all patients considering THR.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
William_Swainson
Affymetrix Selected to Genotype More Than 9,000 Framingham Heart Study Samples - SHARE Project to Help Identify Genetic Variants Associated With Heart, Lung, Blood and Sleep Disorders

New app calculates corona infection risk in rooms - Size of aerosol droplets that virus carriers release strongly influences infectivity
Northern_Norway_Pharmaceutical_Trust

Cell culture: The opportunities and the challenges - The promise of cell culture is accelerating demand, and emphasising the challenges, of this process
Crucell Teams up with ACE BioSciences and Harvard to Accelerate Bacterial Antibody Program
St_John_Ambulance_in_England_and_Wales
Harold_Ridley_(ophthalmologist)
Henry_Suter
